89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California. Show more

Location: 655 Montgomery Street, San Francisco, CA, 94111, United States | Website: https://www.89bio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.606B

52 Wk Range

$4.16 - $11.84

Previous Close

$10.78

Open

$10.70

Volume

1,435,286

Day Range

$10.58 - $11.14

Enterprise Value

832.4M

Cash

638.8M

Avg Qtr Burn

-99.96M

Insider Ownership

0.62%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.